

## FINAL AGENDA

## **Directors Meeting**

Saturday, October 15, 2016 • 8am – 12pm • Baltimore Marriott Inner Harbor at Camden Yards • Grand Ballroom

7:30am	Breakfast
8:00	Welcome  David Knopman, MD CHAIR, ADC EXECUTIVE COMMITTEE; CLINICAL CORE LEADER, MAYO CLINIC
8:05	NIA update  Marie Bernard, MD DEPUTY DIRECTOR, NATIONAL INSTITUTE ON AGING/NIH  Eliezer Masliah, MD, PhD DIRECTOR, DIVISION OF NEUROSCIENCE, NIA/NIH  Creighton Phelps, PhD DEPUTY DIRECTOR, DIVISION OF NEUROSCIENCE, AND DIRECTOR, ADC PROGRAM, NIA/NIH
9:00	Future of ADCs Program update  Barry Greenberg, PhD director of strategy, toronto dementia research alliance
9:10	NACC update Walter A. Kukull, PhD director, national alzheimer's coordinating center
9:25	ADGC, NCRAD, and NIAGADS: GWAS update  Gerard Schellenberg, PhD PI, ALZHEIMER'S DISEASE GENETICS CONSORTIUM  Tatiana Foroud, PhD PI, NATIONAL CELL REPOSITORY ON ALZHEIMER'S DISEASE  Li-San Wang, PhD PI, NIA GENETICS OF ALZHEIMER'S DISEASE DATA STORAGE SITE
9:45	BREAK

## 10:00 SCIENTIFIC SYMPOSIUM

Imaging and CSF biomarkers for classifying persons in the AD spectrum

- The development and evolution of a classification system for AD biomarkers: From A to A/N to A/T/N Clifford R. Jack, Jr., MD Mayo Clinic
- Relationship of biomarker classification for AD to cognition and cognitive decline Elizabeth C. Mormino, PhD — Harvard University
- Interrelationships between imaging and CSF biomarkers for AD Brian Gordon, PhD Washington University in St. Louis
- Functional MR and connectivity in different AD biomarker subgroups
   David Thomas Jones, MD Mayo Clinic